Clients

Recent News
4/24/2012
Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
»
3/12/2012
LensAR Raises $24 Million in Private Financing to Support Commercial Launch of LensAR Laser System
»
2/21/2012
Amsterdam Molecular Therapeutics Receives Request for Further Information from CHMP on Glybera®
»
2/4/2012
Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis Immunotherapy, AGS-003, in Combination with Sunitinib for mRCC
»
Extera Partners is a premier global life sciences strategic partnering and product commercialization firm


































